First DRAIN-HF enrollment in Oregon! Congratulations to Jeffrey Marbach and the team at Oregon Health & Science University on enrolling your first patient in this groundbreaking study for patients with acute decompensated #heartfailure. #Aortix #cardiorenalsyndrome #diureticresistance #clinicaltrials #innovation Also pictured are Aaron Palmer and Ann Hammes from the Procyrion side!
Procyrion, Inc.
Herstellung medizinischer Geräte
Houston, TX 7,770 followers
Developing catheter-based circulatory support devices to address the needs of heart failure and kidney disease patients
Über uns
Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system. Aortix™ is currently in the research and development phase and is not available for sale in any country. (Caution: investigational device. Limited by federal law to investigational use.)
- Website
-
http://www.procyrion.com
External link for Procyrion, Inc.
- Industrie
- Herstellung medizinischer Geräte
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Houston, TX
- Typ
- In Privatbesitz
- Gegründet
- 2005
- Spezialitäten
- Circulatory Assist Devices
Standorte
-
Primäre
Wegbeschreibung erhalten
3900 Essex Lane
Houston, TX 77027, US
Employees at Procyrion, Inc.
Aktualisierungen
-
We’re excited to announce Dr. Oliver G. Abela, MD, FACC and the team at AdventHealth Tampa have enrolled their first patient in the groundbreaking DRAIN-HF trial. Thank you for your commitment to advance treatment options for patients with acute decompensated #heartfailure! #Aortix #cardiorenalsyndrome #diureticresistance #clinicaltrials #innovation
-
-
First DRAIN-HF enrollment in Tampa! Congrats to Dr. Robby Wu and the team at University of South Florida on enrolling your first patient in this groundbreaking study for patients with acute decompensated #heartfailure. #Aortix #cardiorenalsyndrome #diureticresistance #clinicaltrials #innovation
-
-
New DRAIN-HF site alert! We're excited to announce that Lucas Zier, MD, MS and the team at Zuckerberg San Francisco General Hospital have enrolled their first patient in this groundbreaking study for patients with acute decompensated heart failure. We are grateful for your commitment to advance treatment options for #heartfailure patients! #Aortix #cardiorenalsyndrome #diureticresistance #clinicaltrials #innovation
-
-
Another 1st DRAIN-HF patient enrollment is in the books! Congrats to Drs. James Lyons, Rajeev Narayan, and the team at Nuvance Health Vassar Brothers Medical Center on enrolling your first patient in this important study evaluating Aortix for treating patients with acute decompensated heart failure. We are grateful for your commitment to advance treatment options for #heartfailure. #Aortix #cardiorenalsyndrome #diureticresistance #clinicaltrials #innovation
-
-
LISTEN NOW: Our CEO Eric Fain shares his insights on leading a #medtech company with Scott Nelson of Medsider. Eric Fain Scott Nelson Medsider https://lnkd.in/gtnQzjAm
"In the past, FDA approval was 80% of the focus and reimbursement was 20%. I'd say those priorities are closer to equal today. The reimbursement piece of this has become more and more important and also more challenging. You really have two customers. You have FDA, and you have CMS, which has a different perspective. It truly goes hand in hand.” Dr. Eric Fain is an MD with a passion for #medtech. His #medicaldevices career began when he joined Ventritex. Over the next 30 years, and through the company’s acquisition by St. Jude Medical, Eric has held a number of leadership roles and eventually became Group President through St. Jude’s exit to Abbott. He’s now the CEO of Procyrion, Inc., a startup developing Aortix, an advanced percutaneous mechanical circulatory support device for patients with heart and renal failure. In this Medsider interview, Eric and Scott Nelson discuss: ☕ Craft a compelling narrative for investors early on, focusing on your unique value proposition and growth strategy. Prioritize spending on essentials and consider outsourcing non-core functions to conserve resources to extend your runway. 💼 Put yourself in the acquirer’s shoes. Build robust clinical evidence and establish a strong quality management system to derisk your startup and enhance scalability and value. 🎯 Define your target market early to inform regulatory and reimbursement strategies. Address coverage challenges early on and engage CMS. Explore partnerships with private payers for both learning and clinical trial opportunities. Check out the full interview link in the comments. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We just launched Medsider Mentors Volume V, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.
-
Congrats to Dr. Richard Cheng and the team at UCSF on setting a new DRAIN-HF study record! The UCSF team enrolled 2 patients in 1 week as we work together to advance treatment options for patients with acute decompensated #heartfailure. #cardiorenalsyndrome #diureticresistance #clinicaltrials #Aortix #innovation
-
-
Our DRAIN-HF trial evaluating the #Aortix pump for acute decompensated #heartfailure patients is well underway. Congrats to Henry Ford Hospital and John Muir Hospital for enrolling multiple patients in this important study! #clinicaltrials #cardiorenalsyndrome #diureticresistance #innovation
-
Another DRAIN-HF site begins patient enrollment! Congrats to Dr. Miguel Alvarez Villela and the Northwell Health Lenox Hill team on enrolling your first patient in this groundbreaking trial for #heartfailure patients. #clinicaltrials #cardiorenalsyndrome #diureticresistance #Aortix #innovation
-
-
BREAKING NEWS: We are proud to be recognized as a #Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix technology and the potential it has to change the way patients with acute decompensated #heartfailure and cardiorenal syndrome are treated. https://lnkd.in/gR47YYhU